NASDAQ:THAR Tharimmune (THAR) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free THAR Stock Alerts $0.37 +0.01 (+2.78%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.36▼$0.3750-Day Range$0.36▼$0.4752-Week Range$0.34▼$31.50Volume62,089 shsAverage Volume228,185 shsMarket Capitalization$4.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Tharimmune alerts: Email Address Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About Tharimmune Stock (NASDAQ:THAR)Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.Read More THAR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart THAR Stock News HeadlinesApril 24, 2024 | finance.yahoo.comTharimmune, Inc. (THAR)April 18, 2024 | morningstar.comTharimmune Inc THARApril 27, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. April 16, 2024 | investing.comTharimmune forms advisory board to guide drug developmentFebruary 21, 2024 | msn.comTharimmune’s buccal film liver drug demonstrates effectiveness in Phase I trialFebruary 20, 2024 | msn.comTharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver DiseaseFebruary 20, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 20, 2024 | finance.yahoo.comTharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateApril 27, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. February 9, 2024 | msn.comTharimmune’s Active Common Stock Shares UpdateFebruary 5, 2024 | finance.yahoo.comTharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary CholangitisJanuary 29, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business UpdateDecember 11, 2023 | finance.yahoo.comTharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease PatientsNovember 30, 2023 | finance.yahoo.comTharimmune, Inc. Announces Closing of $11 Million Public OfferingNovember 30, 2023 | msn.comWhy Tharimmune Stock (THAR) Is Down 70% TodayNovember 29, 2023 | msn.comWhy Is Liver Disease Focused Tharimmune Stock Trading Higher Today?November 29, 2023 | marketwatch.comTharimmune Shares Hit 52-Week Low After Public Offering PricesNovember 29, 2023 | msn.comTharimmune announces pricing of $10 million public offeringNovember 29, 2023 | markets.businessinsider.comCrude Oil Surges 2%; Tharimmune Shares PlummetNovember 29, 2023 | finance.yahoo.comTharimmune, Inc. Announces Pricing of $10 Million Public OfferingNovember 28, 2023 | investorplace.comWhy Is Tharimmune (THAR) Stock Down 70% Today?November 7, 2023 | investorplace.comWhy Is Tharimmune (THAR) Stock Up 113% Today?See More Headlines Receive THAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tharimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)5/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:THAR Previous SymbolNASDAQ:THAR CUSIPN/A CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($16.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-217.25% Return on Assets-159.07% Debt Debt-to-Equity RatioN/A Current Ratio6.03 Quick Ratio6.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.03 per share Price / Book0.03Miscellaneous Outstanding Shares11,740,000Free Float11,462,000Market Cap$4.33 million OptionableNot Optionable Beta1.63 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Randy D. Milby MBA (Age 70)President, Chairman & CEO Comp: $593.75kMr. Sireesh Appajosyula Pharm.D. (Age 48)COO & Director Comp: $584.8kMr. Thomas P. Hess CPA (Age 60)MBA, Chief Financial Officer Key CompetitorsPetros PharmaceuticalsNASDAQ:PTPICingulateNASDAQ:CINGArtelo BiosciencesNASDAQ:ARTLLongeveronNASDAQ:LGVNExicureNASDAQ:XCURView All CompetitorsInsidersRandy MilbyBought 29,000 shares on 12/15/2023Total: $14,500.00 ($0.50/share)Randy MilbyBought 10,000 shares on 11/30/2023Total: $10,000.00 ($1.00/share)View All Insider Transactions THAR Stock Analysis - Frequently Asked Questions How have THAR shares performed in 2024? Tharimmune's stock was trading at $0.5090 on January 1st, 2024. Since then, THAR shares have decreased by 27.5% and is now trading at $0.3691. View the best growth stocks for 2024 here. Are investors shorting Tharimmune? Tharimmune saw a increase in short interest in April. As of April 15th, there was short interest totaling 103,400 shares, an increase of 37.3% from the March 31st total of 75,300 shares. Based on an average daily trading volume, of 488,400 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.9% of the company's shares are short sold. View Tharimmune's Short Interest. When is Tharimmune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our THAR earnings forecast. When did Tharimmune's stock split? Shares of Tharimmune reverse split on Tuesday, November 21st 2023. The 1-25 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Tharimmune? Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:THAR) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.